异动解读|ImmunityBio, Inc.盘中上涨4.26%,Anktiva海外推进与临床进展提振情绪

行情直击
Nov 17

11月17日,ImmunityBio, Inc.盘中上涨4.26%,报6.1914美元/股,成交额318.01万美元。

消息面上,公司近期围绕Anktiva的海外商业化与临床推进持续释放进展,带动市场重新评估产品落地预期。

具体看,Anktiva联合BCG已获以色列卫生部批准用于特定膀胱癌成人患者治疗,注册许可预计未来数周内发放;欧洲方面,公司已宣布首批患者接受治疗;同时其在非肌层浸润性膀胱癌注册性试验中达到主要终点,并计划于年底前提交补充生物制品许可申请。尽管此前第三季度营收4884.1万美元、低于预期的5925万美元,且每股亏损扩大至0.18美元,但近期产品进展对股价形成一定支撑。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10